ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that it will be presenting one podium presentation and two abstracts at the Military Health System Research Symposium (MHSRS) August 27-30, 2017 in Washington, D.C. BioTime has recently released data from its two lead programs in medical aesthetics and ophthalmology and is now exploring ways to address serious unmet needs for trauma and combat-related injuries.
The podium presentation and two abstracts include:
- The podium presentation titled, “Restoring Light Perception with Retinal Tissue Grafting Derived from Human Pluripotent Stem Cells” will be presented by Dr. Igor Nasonkin, BioTime’s head of research, on Monday, August 28th during the Medical Advancements in Operational and Clinical Vision Protection and Treatment session. This presentation outlines the potential use of BioTime’s pluripotent cell technology to help the body restore vision following blast exposure. The preclinical study demonstrates positive results following grafting of these cells into sub-retinal tissue, as well as improvement in tracking vision over an eight month period.
- The abstract titled, “Repair of Trauma-Induced Subcutaneous Contour Defects Using Autologous Adipose Derived Stem Cells Implanted in Renevia® Hydrogel Matrix” will be presented by Dr. Thomas Zarembenski, BioTime’s head of external R&D, on Tuesday, August 29th during the Head, Neck & Facial Trauma/ Otolaryngology & Plastic Surgery Demo session. This abstract describes safety data following the use of Renevia® in facial contour defects as a result of trauma.
- The abstract titled, “Vision Preservation Following Blast Injury Through Continuous Paracrine Delivery of Trophic Factors to Degenerating Optic Nerve and Retina” will be presented by Dr. Nasonkin, on Tuesday, August 29th during the Medical Advancements in Operational and Clinical Vision Protection and Treatment session. This abstract outlines two methodologies used to differentiate pluripotent cells, followed by their implantation in mouse models with degenerating optic nerve and retinal tissue. The study demonstrates successful, tumor-free integration with retinal tissue, which is expected to slow, halt or improve vision degeneration over time.
“The MHSRS symposium is hosted by the Department of Defense (DoD) and it highlights medical solutions that may lead to therapies to further protect troops and veterans,” said Adi Mohanty, co-CEO of BioTime. “We believe our technologies can help address issues associated with trauma, reconstruction or other combat-related injuries. We look forward to working with the Department of Defense towards expanding the potential uses of our platforms and products.”
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent cells and cell/drug delivery. The foundation of BioTime’s core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. The foundation of the Company’s cell delivery platform is its HyStem® cell and drug delivery matrix technology. The Company’s current clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell/drug delivery. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. and OncoCyte Corporation.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.
To receive ongoing BioTime corporate communications, please click on the following link to join the Company’s email alert list: http://news.biotimeinc.com.
Forward-Looking Statements
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime, Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the “Risk Factors” section of its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. BioTime specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.